Kunes P, Holubcova Z, Kolackova M, Krejsek J
Department of Cardiac Surgery, Charles University in Prague, School of Medicine in Hradec Kralove, Hradec Kralove, Czech Republic.
Thorac Cardiovasc Surg. 2010 Dec;58(8):443-9. doi: 10.1055/s-0030-1250436. Epub 2010 Nov 26.
Interleukin-33 is a newly recognized cytokine of the IL-1 family. Unlike its other members IL-1α, IL-1β and IL-18, interleukin-33 induces predominantly Th2-skewed immune responses. In this context, the effects of IL-33 are mostly anti-inflammatory. However, depending on the actual cytokine and cellular milieu, IL-33 can promote both Th1 and Th2 immune reactions. Most importantly for cardiology and cardiac surgery, IL-33 has emerged to represent the as yet unknown ligand of the orphan receptor ST2. Before the advent of IL-33, the ST2 receptor, currently recognized as the soluble one of its two isoforms, was considered to be an unfavorable prognostic marker in myocardial infarction, congestive heart failure and trauma/sepsis shock patients. Now we know that IL-33, when bound to the cellular membrane-anchored ST2L isoform of the receptor, can have certain beneficial effects on the aforementioned conditions. Various forms of IL-33 interaction with the respective isoforms of its cognate receptor are discussed here. The focus is on physiological and prognostic values in cardiac patients.
白细胞介素-33是白细胞介素-1家族新发现的一种细胞因子。与该家族的其他成员白细胞介素-1α、白细胞介素-1β和白细胞介素-18不同，白细胞介素-33主要诱导偏向Th2的免疫反应。在这种情况下，白细胞介素-33的作用大多是抗炎的。然而，根据实际的细胞因子和细胞环境，白细胞介素-33可以促进Th1和Th2免疫反应。对心脏病学和心脏外科手术来说最重要的是，白细胞介素-33已被证实是孤儿受体ST2的未知配体。在白细胞介素-33出现之前，ST2受体（目前被认为是其两种异构体中的可溶性异构体）在心肌梗死、充血性心力衰竭以及创伤/脓毒症休克患者中被视为不良预后标志物。现在我们知道，白细胞介素-33与受体的细胞膜锚定异构体ST2L结合时，可对上述病症产生某些有益作用。本文讨论了白细胞介素-33与其同源受体各异构体的各种相互作用形式。重点是其在心脏病患者中的生理和预后价值。
